Candel Therapeutics Inc (CADL) Stock Price, Quote & News

Company Profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 916 5445

Website: www.candeltx.com

Address:

117 Kendrick Street, Suite 450, Needham, United States

deporte1800 Feb. 3 at 7:08 AM

$CADL paet 5. 2. The big difference: “Local vs. Systemic” Opdivo and Imdelltra: These are systemic treatments (they are injected into a vein and travel throughout the body). This increases survival, but also the risk of the immune system attacking healthy tissue. CAN-2409: This is a direct intratumoral injection. The adenovirus infects only the tumor cells. This creates an “in situ vaccine” that trains the immune system. According to the reported data, no dose-limiting toxicities have been observed. 3. Impact on FDA approval For the FDA, the efficacy vs. safety ratio is what defines accelerated approval: Imdelltra was approved despite its high toxicity because its efficacy was very good in a terminal disease. CAN-2409 has the “perfect combo”: it doubles survival (25 months vs. 12) and has almost zero toxicity. continue

1 · Reply

deporte1800 Feb. 3 at 7:03 AM

$CADL Part 4. What does this mean for Candel (CAN-2409)? Candel is in a very interesting intermediate position: Like Opdivo: CAN-2409 is already being tested in other cancers (prostate and pancreas), and the FDA has already given it RMAT (Regenerative Medicine Advanced Therapy) status in prostate cancer, which means that the agency already “knows” and “trusts” the drug's technical platform. As Imdelltra: It would be its first commercial approval, but by doubling survival (from 12 to 25 months), it would fall into the category of disruptive therapy. Conclusion: The FDA does not need the drug to be approved for anything else (such as Imdelltra), but if it has already seen positive data in other organs (such as with Candel's RMAT in the prostate), the path to accelerated approval in the lung becomes much smoother.

0 · Reply

deporte1800 Feb. 3 at 6:33 AM

$CADL Part 3. allowing Phase 2 data to be used for potential approval if the results are “exceptional.” What could slow down approval? Even if survival rates are high, the FDA has historically required: Safety: The drug must not be more toxic than chemotherapy. So far, CAN-2409's safety profile is superior. Quality of life: That those extra months are spent in “good health,” not just bedridden. Consistency: That the data does not come from too small a group (currently, the study is large enough to be considered by the FDA). Conclusion: The FDA does not usually ignore data that doubles standard survival. If Candel presents these 25 months in Q1, it is very likely that they will begin the Accelerated Approval process this year.

0 · Reply

deporte1800 Feb. 3 at 6:31 AM

$CADL Part 2. becoming traditional approval in less than a year after confirming the data. 2. Is going from 12 to 25 months sufficient? Yes, it is more than sufficient. For the FDA, a +13-month improvement in median survival in a second-line population (patients who have already failed other treatments) is almost unheard of. In 2025, drugs such as Zongertinib and Sevabertinib obtained Accelerated Approval based on much more modest response and survival rates in populations with specific biomarkers. If CAN-2409 maintains the 25 months, Candel has a strong argument for applying for Breakthrough Therapy designation, which requires the FDA to collaborate closely on the design of phase 3 to accelerate registration. 3. The “RMAT” and “Fast Track” factor Candel already knows how to navigate this. They have received RMAT (Regenerative Medicine Advanced Therapy) designation for their prostate trial. This designation is the ultimate “fast track,”

0 · Reply

deporte1800 Feb. 3 at 6:25 AM

$CADL Part 1. Very interesting, stay tuned for the update on the lung trial data that will be released very soon! Historically, the FDA has proven to be pragmatic and flexible when survival data is as compelling as that projected by Candel. A jump from 12 to 25 months in overall survival (OS) is considered, in regulatory terms, a “transformative clinical benefit.” Here's how the FDA has acted in similar cases and what precedents exist: 1. The “100% Improvement” Precedent Historically, the FDA grants accelerated or traditional approvals based on the magnitude of the benefit: Immunotherapies (Checkpoint Inhibitors): When drugs such as Nivolumab (Opdivo) were shown to double survival compared to chemotherapy (docetaxel) in lung cancer, the FDA granted an expedited review of only 3.2 months for approval. Targeted Therapies: Drugs such as Tarlatamab (Imdelltra) for small cell lung cancer received accelerated approval after a robust phase 2 trial,

0 · Reply

kinosouppp Feb. 3 at 2:45 AM

$CADL One company is pre-commercial with early/mid-stage programs. The other has Phase 3 prostate cancer data and non-dilutive financing. If you’re arguing share price instead of catalysts, you’re not doing real analysis.

0 · Reply

Ten_Bagger_Hunter Feb. 3 at 2:24 AM

$CADL CADL is more than just a biotech company; it is a strategic asset driving a paradigm shift in the field of oncolytic viruses. CAN-2409 has already demonstrated efficacy and safety in localized prostate cancer through Phase 3 clinical trials, possessing the disruptive power to shake up a market that has remained stagnant for decades. Its ascent to blockbuster status within the single indication of prostate cancer appears to be only a matter of time, while its scalability into NSCLC and pancreatic cancer offers additional upside potential. From the perspective of BP, CADL represents an optimal "Low Risk-High Return" investment to defend against patent cliffs and strengthen immunotherapy portfolios. Comprehensive market analysis suggests that Candel’s acquisition price will start at a minimum of $2.5 billion, with the potential to reach a valuation of up to $8 billion should a competitive bidding environment emerge.

2 · Reply

Xanderzzzzzzz Feb. 3 at 1:49 AM

$CADL $IOVA $CATX The 2026-2030 patent cliff is here, and it’s centered around a small group of extremely high revenue drugs. • Eliquis - ~$12.2B (2026) • Trulicity - ~$7.1B (2027) • Ocrevus - ~$7.1B (2027) • Keytruda - ~$25.0B (2028) • Opdivo - ~$9.0B (2028) • Gardasil 9 - ~$8.9B (2028) • Darzalex - ~$9.7B (2029) • Cosentyx - ~$4.8B (2029) • Enbrel - ~$3.7B (2029) That’s tens of billions in annual sales reaching the edge of exclusivity in just a few years. This window is going to define strategic decisions across pharma, from pipeline timing to partnering, lifecycle planning, and launch execution, well into the next decade

0 · Reply

stu4 Feb. 3 at 1:43 AM

$CADL ..no fake bear ..made 50% in 10 months , SHORT Now it’s a penny stock again, a year later and all your bullshit

1 · Reply

stu4 Feb. 3 at 1:40 AM

$CADL No , the resident truthful soul KYMR ..NO DRUGS ..NO BLA’s ,..NO NDA’s $70 CADL?..no Drugs ..no BLA …NO NDA’s …….$5.80 Guess we know where credibility is alive and where bullshit lies !!!!

1 · Reply

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 17, 2025, 4:05 PM EST - 2 months ago

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

Nov 13, 2025, 8:25 AM EST - 2 months ago

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

TRIN

Nov 4, 2025, 9:00 AM EST - 3 months ago

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

Nov 3, 2025, 8:05 AM EST - 3 months ago

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

Oct 16, 2025, 8:05 AM EDT - 3 months ago

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

Oct 14, 2025, 8:10 AM EDT - 3 months ago

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

Oct 14, 2025, 8:10 AM EDT - 3 months ago

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

TRIN

Oct 14, 2025, 8:05 AM EDT - 3 months ago

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

Oct 13, 2025, 10:22 AM EDT - 4 months ago

Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now

Oct 3, 2025, 9:05 AM EDT - 4 months ago

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

Sep 29, 2025, 8:05 AM EDT - 4 months ago

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 17, 2025, 8:05 AM EDT - 4 months ago

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 7, 2025, 10:53 AM EDT - 5 months ago

Candel Therapeutics: Potentially The Next Exciting Oncology Story

Sep 5, 2025, 12:47 PM EDT - 5 months ago

Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors

Sep 2, 2025, 8:05 AM EDT - 5 months ago

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.

Aug 28, 2025, 8:05 AM EDT - 5 months ago

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 14, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Jul 30, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 24, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Jul 9, 2025, 8:05 AM EDT - 7 months ago

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

Jun 24, 2025, 9:05 AM EDT - 7 months ago

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

Jun 23, 2025, 8:05 AM EDT - 8 months ago

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

Jun 6, 2025, 8:05 AM EDT - 8 months ago

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

May 28, 2025, 8:05 AM EDT - 8 months ago

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

May 27, 2025, 8:05 AM EDT - 8 months ago

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

May 22, 2025, 5:05 PM EDT - 9 months ago

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

May 13, 2025, 8:05 AM EDT - 9 months ago

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 6, 2025, 8:05 AM EDT - 9 months ago

Candel Therapeutics to Present at Upcoming Investor Conferences

Apr 23, 2025, 4:05 PM EDT - 10 months ago

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Apr 1, 2025, 8:01 AM EDT - 10 months ago

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Mar 26, 2025, 4:05 PM EDT - 11 months ago

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Mar 20, 2025, 8:00 AM EDT - 11 months ago

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Mar 18, 2025, 8:00 AM EDT - 11 months ago

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D.

Mar 13, 2025, 4:15 PM EDT - 11 months ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Feb 25, 2025, 4:52 PM EST - 1 year ago

Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data

Feb 25, 2025, 8:00 AM EST - 1 year ago

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Feb 20, 2025, 10:45 AM EST - 1 year ago

Candel Therapeutics: Entering Its Pivotal Year

Jan 13, 2025, 8:00 AM EST - 1 year ago

Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

Jan 2, 2025, 11:46 PM EST - 1 year ago

Best-Performing Stocks Of 2024

APP BYRN DAVE INOD JANX LUNR MSTR

Dec 16, 2024, 4:01 PM EST - 1 year ago

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 13, 2024, 8:53 AM EST - 1 year ago

Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session

EGHT

Dec 12, 2024, 11:00 PM EST - 1 year ago

Candel Therapeutics Announces Pricing of Public Offering

Dec 12, 2024, 4:51 PM EST - 1 year ago

Candel Therapeutics Announces $80 Million Proposed Public Offering

Dec 11, 2024, 12:19 PM EST - 1 year ago

Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight

Dec 11, 2024, 9:19 AM EST - 1 year ago

Candel Therapeutics Stock Surges Over 100% - Here's Why

Dec 11, 2024, 7:09 AM EST - 1 year ago

Candel Therapeutics' cancer drug meets late-stage trial goals

Dec 11, 2024, 7:00 AM EST - 1 year ago

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

Nov 5, 2024, 9:00 AM EST - 1 year ago

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

Nov 1, 2024, 12:40 PM EDT - 1 year ago

Candel Therapeutics: A Low-Price Oncolytic Virus Plays Further Along Than You Think

deporte1800 Feb. 3 at 7:08 AM

1 · Reply

deporte1800 Feb. 3 at 7:03 AM

0 · Reply

deporte1800 Feb. 3 at 6:33 AM

0 · Reply

deporte1800 Feb. 3 at 6:31 AM

0 · Reply

deporte1800 Feb. 3 at 6:25 AM

0 · Reply

kinosouppp Feb. 3 at 2:45 AM

0 · Reply

Ten_Bagger_Hunter Feb. 3 at 2:24 AM

2 · Reply

Xanderzzzzzzz Feb. 3 at 1:49 AM

0 · Reply

stu4 Feb. 3 at 1:43 AM

$CADL ..no fake bear ..made 50% in 10 months , SHORT Now it’s a penny stock again, a year later and all your bullshit

1 · Reply

stu4 Feb. 3 at 1:40 AM

1 · Reply

stu4 Feb. 3 at 1:36 AM

$CADL were that the case this would be at $70…like KYMR No drug approved , in phase 1/b , just like this pos !!! BUT BUT , credible execs over there in Cambridge, Mass. Slime balls in Watertown , Ma at CADL

1 · Reply

stu4 Feb. 3 at 1:34 AM

$CADL which means you have no serious cash to play this stock ..you are a pink sheets guy , lol

1 · Reply

Kittyc803 Feb. 2 at 10:52 PM

$CADL Loving the dips . Tx

2 · Reply

Xanderzzzzzzz Feb. 2 at 10:32 PM

$CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-inducement-grants-under-nasdaq

2 · Reply

XelenaL Feb. 2 at 10:23 PM

$CADL i know a lot of hopes are on the new data. How confident are you guys on these data? If the data is not good how low can this drop?

1 · Reply

XelenaL Feb. 2 at 10:16 PM

$CADL i know a lot of hopes are on the new data. How confident are you guys on these data? If the data is not good how low can this drop?

1 · Reply

chrundel Feb. 2 at 9:18 PM

$CADL baffling that it can’t hold any daily gains 🧐

2 · Reply

Drcando Feb. 2 at 9:08 PM

$CADL my recent normal statement again Piss Poor Volumn Smells like 🚀 fuel ⛽️ gonna be loading in 2026 Imho

0 · Reply

1Loonie2Toonie Feb. 2 at 8:47 PM

$CADL think the short thesis is that they will need to dilute this year if no deal is made..

1 · Reply

Drcando Feb. 2 at 6:38 PM

$CADL IMHO We gonna need seat belts buckled when this 🚀 lifts off I'm adding more as I can my business is picking up so I'll throw my extra cash into this 🐂

1 · Reply

Stocksprofessional Feb. 2 at 6:24 PM

$CADL Just placed a good-till-cancel order for my 28,200 CADL shares at $80 — and I couldn’t be more confident. This isn’t a trade, it’s a high-conviction, long-term bet. I’m fully strapped in for the ride, focused on the bigger picture and what’s coming, not the noise along the way. The thesis is intact, the setup is compelling, and the upside speaks for itself. Bullish as it gets — long, strong, and holding with zero hesitation. 🚀📈

0 · Reply

Deeconomics Feb. 2 at 5:25 PM

$CADL Candel Therapeutics prioritizing "Robust over Rushed" BLA submission is following the strategy of their successful neighboring drug company in Massachusetts. Vertex Pharmaceuticals has built a dominant, multibillion-dollar portfolio by employing a strategy of "serial innovation," The Iterative "Slow-and-Steady" Approach prioritizes deep scientific understanding, high-barrier-to-entry, and ensuring long-term market dominance rather than immediate, rushed regulatory approval. The company takes the time to run extensive, high-quality clinical trials to ensure that when they do file a Biologics License Application, it is supported by robust data, often utilizing "rolling submissions" that allow them to submit data in stages to ensure a strong, comprehensive package. Blockbuster Drugs Created Kalydeco (ivacaftor): The first breakthrough CF drug. Trikafta: The flagship triple-combination therapy that brought in roughly $8.9 billion in a single year (2023). And other blockbusters.

0 · Reply

Market Cap	320.60M
Revenue (ttm)	0.00
Net Income (ttm)	-55.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.06

Volume	419,100
Avg Vol	816,176
Day's Range	N/A - N/A
Shares Out	54.90M
Stochastic %K	20%
Beta	-0.93
Analysts	Strong Sell
Price Target	$18.62